Results 201 to 210 of about 49,192 (255)

Cellular and inflammatory characteristics of patient‑derived glioblastoma organoids during <i>in vitro</i> cultivation. [PDF]

Oncol Rep
Nojszewski J, Schröder NO, Clüver J, Holler J, Ahmeti H, Synowitz M, Held-Feindt J.   +6 more
europepmc   +1 more source

Targeting the CXCL12/CXCR4 pathway by an optimized derivative or EPI-X4 preserves chondrocyte function and offers a novel therapeutic approach in rheumatic diseases. [PDF]

Arthritis Res Ther
Ruths L, de Hesselle H, Haußner F, Albers S, Harms M, Freitag T, Münch J, Riegger J.   +7 more
europepmc   +1 more source

The role of chemokines and their receptors in cardiovascular diseases. [PDF]

Front Immunol
Srikanth S, DeVito L, Constantinesco NJ, Gopal R.   +3 more
europepmc   +1 more source

The CXCL12/CXCR4 Axis in Sepsis-Induced Acute Lung Injury: Mechanisms and Therapeutic Potential. [PDF]

Curr Issues Mol Biol
Luo R, Fan Q, Chen Q, Nie Z, Dan L, Xie S.   +5 more
europepmc   +1 more source

Chemokines and their receptors in oral squamous cell carcinoma: mechanisms, clinical significance, and therapeutic implications. [PDF]

Front Immunol
Li D, Chen S, Ji J, Wang Z, Zhou H, Liao Z, Tang Q.   +6 more
europepmc   +1 more source

CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies. [PDF]

Signal Transduct Target Ther
Shu P, Guo F, Qin D, Zou L, Ma Q, Zhang B, Gao G, Chen Y, He X, Jiang M, Liu N, Zhou K, Zhao J, Lei Y, Gao Y, Zhang Y, Zeng Y, Feng M, Li X, Li D, Wang Y.   +20 more
europepmc   +1 more source

CXCR4-antagonistic peptide-decorated lipid nanoparticles for co- delivery of AML1-ETO siRNA to enhance chemotherapy in refractory AML. [PDF]

J Hematol Oncol
Peng X, Gu R, Wang T, Jiang C, Xing H, Meng J, Wen T, Liu J, Wang J, Xu H.   +9 more
europepmc   +1 more source

Initiation of Tertiary Lymphoid Structures for Cancer Immunotherapy. [PDF]

Research (Wash D C)
Zou JY, Li ZT, Wang ZC, Li H, Sun ZJ.
europepmc   +1 more source

Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy. [PDF]

Cell Oncol (Dordr)
Nasir Kansestani A, Zare ME, Zhang J.
europepmc   +1 more source